HK1079519A1 - Furyl compounds - Google Patents

Furyl compounds

Info

Publication number
HK1079519A1
HK1079519A1 HK05111483A HK05111483A HK1079519A1 HK 1079519 A1 HK1079519 A1 HK 1079519A1 HK 05111483 A HK05111483 A HK 05111483A HK 05111483 A HK05111483 A HK 05111483A HK 1079519 A1 HK1079519 A1 HK 1079519A1
Authority
HK
Hong Kong
Prior art keywords
compounds
furyl compounds
furyl
compositions
therapy
Prior art date
Application number
HK05111483A
Other languages
English (en)
Inventor
Hui-Fang Chang
Yan Li
Eifion Phillips
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201186A external-priority patent/SE0201186D0/xx
Priority claimed from SE0203607A external-priority patent/SE0203607D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1079519A1 publication Critical patent/HK1079519A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
HK05111483A 2002-04-18 2005-12-14 Furyl compounds HK1079519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201186A SE0201186D0 (sv) 2002-04-18 2002-04-18 Furyl compounds
SE0203607A SE0203607D0 (sv) 2002-12-04 2002-12-04 Furyl compounds
PCT/SE2003/000613 WO2003087102A1 (en) 2002-04-18 2003-04-15 Furyl compounds

Publications (1)

Publication Number Publication Date
HK1079519A1 true HK1079519A1 (en) 2006-04-07

Family

ID=29253788

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111483A HK1079519A1 (en) 2002-04-18 2005-12-14 Furyl compounds

Country Status (16)

Country Link
US (1) US7417049B2 (xx)
EP (1) EP1499618B1 (xx)
JP (1) JP4511195B2 (xx)
KR (1) KR20040099447A (xx)
CN (1) CN1325500C (xx)
AT (1) ATE484508T1 (xx)
AU (1) AU2003225456B2 (xx)
BR (1) BR0309343A (xx)
CA (1) CA2482311C (xx)
DE (1) DE60334536D1 (xx)
HK (1) HK1079519A1 (xx)
IL (1) IL164509A0 (xx)
MX (1) MXPA04010191A (xx)
NO (1) NO20044996L (xx)
NZ (1) NZ561794A (xx)
WO (1) WO2003087102A1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AP1635A (en) 2001-10-02 2006-07-14 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
ES2348282T3 (es) * 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
US7544693B2 (en) 2003-10-21 2009-06-09 Astrazeneca Ab Spirofuropyridine aryl derivatives
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2307389B1 (en) 2008-06-20 2013-01-23 AstraZeneca AB Dibenzothiazepine derivative and use thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
SG185594A1 (en) 2010-05-17 2012-12-28 Envivo Pharmaceuticals Inc A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2011149862A1 (en) 2010-05-27 2011-12-01 Targacept, Inc. Nicotinic receptor non-competitive antagonists modulators
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
EP2953940B1 (en) 2013-02-07 2018-08-22 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
EP3215512A1 (en) * 2014-11-04 2017-09-13 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
CN108018049B (zh) * 2016-10-28 2019-09-27 西安近代化学研究所 具有5,6-二氟取代苯并呋喃环的液晶化合物
CN108003895B (zh) * 2016-10-28 2019-04-19 西安近代化学研究所 一种向列相液晶组合物及其显示元件
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
KR20210005176A (ko) 2018-05-10 2021-01-13 조에티스 서비시즈 엘엘씨 내부기생충성 뎁시펩타이드
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
SI1397366T1 (sl) * 2001-06-01 2007-06-30 Astrazeneca Ab Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji
ES2348282T3 (es) * 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.

Also Published As

Publication number Publication date
EP1499618B1 (en) 2010-10-13
CN1325500C (zh) 2007-07-11
KR20040099447A (ko) 2004-11-26
JP2005533012A (ja) 2005-11-04
ATE484508T1 (de) 2010-10-15
CN1662541A (zh) 2005-08-31
US20050176745A1 (en) 2005-08-11
WO2003087102A1 (en) 2003-10-23
NO20044996L (no) 2005-01-18
CA2482311A1 (en) 2003-10-23
JP4511195B2 (ja) 2010-07-28
AU2003225456A1 (en) 2003-10-27
AU2003225456B2 (en) 2009-02-05
NZ561794A (en) 2008-11-28
IL164509A0 (en) 2005-12-18
CA2482311C (en) 2009-12-08
US7417049B2 (en) 2008-08-26
DE60334536D1 (de) 2010-11-25
EP1499618A1 (en) 2005-01-26
BR0309343A (pt) 2005-02-15
MXPA04010191A (es) 2005-02-03

Similar Documents

Publication Publication Date Title
HK1079519A1 (en) Furyl compounds
HK1079522A1 (en) Thienyl compounds
HK1080470A1 (en) Heterocyclic compounds
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
SE0202463D0 (sv) Novel compounds
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
WO2004062613A3 (en) Hiv integrase inhibitors
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
SE0401970D0 (sv) Novel compounds
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
DE60330651D1 (en) C3-cyanoepothilonderivate
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
SE0203070D0 (en) Novel compounds
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
SE0203303D0 (sv) Novel Compounds
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
HK1091816A1 (en) Diphenylurea derivatives and their use as chloride channel blockers
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130415